close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

1.465 +0.105 (+7.72%)
Streaming Delayed Price Updated: 11:34 AM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
From CEL-SCI Corporation
Via Business Wire
News headline image
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Corporation Announces Pricing of Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
From CEL-SCI Corporation
Via Business Wire
InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes $7.2 Million Public Offering
Via Investor Brand Network
News headline image
CEL-SCI Reports Fiscal Second Quarter 2026 Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Corporation Announces Pricing of Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal First Quarter 2026 Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal 2025 Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of $10 Million Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of $10 Million Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Proposed Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Proposed Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Combination of Common Stock
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
From CEL-SCI Corporation
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.